



## Treat the patient, not the result

**To the Editor:** Several episodes of nursing and laboratory staff at a specialist tuberculosis (TB) hospital presenting with flu-like symptoms, who on further investigation were found to have acid-fast bacilli in their sputum yet normal chest radiographs, have occurred. In many instances, in the absence of other evidence of TB, these staff were not initiated on anti-TB treatment. Serial sputum investigations remained negative and the symptoms disappeared. Similarly, in the same institution there have been several reports of patients referred with a microbiological diagnosis of multi- or extensively drug-resistant tuberculosis. Owing to the protracted period of time needed to grow these organisms, the individuals concerned are commenced on first-line TB treatment. By the time the susceptibility results are received (usually several months later) and the patients referred to the specialist TB hospital for further management, both clinical and radiological improvement in response to first-line TB treatment has taken place, which suggests that there might have been some contact with TB (drug-susceptible or resistant), and the bacillus could have infected and behaved as a commensal for a short period and not caused disease in the 'carrier'. This scenario is more relevant today, with the prevalence of MDR and XDR TB. If a chest radiograph is reported as clear by an experienced reader, and the individual is asymptomatic, then the sputum test should be repeated, including culture and susceptibility testing, before embarking on therapy with potentially toxic second-line TB drugs. Health workers should be cognisant of these confounders and remember to treat the patient – and not laboratory reports or radiographs.

### Nesri Padayatchi

Department of Community Health  
University of KwaZulu-Natal  
Durban  
Padayatchin@ukzn.ac.za

### John Quantrill

King George V Hospital  
Durban

1. Demissie A, Leyten EM, Abebe M, *et al.* Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with *Mycobacterium tuberculosis*. *Clin Vaccine Immunol* 2006; 13(2): 179-186.
2. Hussain R, Talat N, Shahid F, Dawood G. Longitudinal tracking of cytokines after acute exposure to tuberculosis: association of distinct cytokine patterns with protection and disease development. *Clin Vaccine Immunol* 2007; 14(12): 1578-1586.

## (ARV-) Free State? The moratorium's threat to patients' adherence and the development of drug-resistant HIV

**To the Editor:** Despite early fears that people living with HIV (PLWHs) in Africa would not be able to adhere to antiretrovirals (ARVs),<sup>1,2</sup> research has shown that the proportion of PLWHs reporting  $\geq 95\%$  adherence in sub-

Saharan Africa is higher than that in North America.<sup>3</sup> However, maintaining adherence is complex, and several factors affect patient ability to access and adhere to ARVs: patient characteristics and context, ARV regimen, clinical situation and the patient/health staff relationship.<sup>4</sup>

In October 2008, the new Minister of Health announced that 550 000 PLWHs – the highest number in the world – were on ARVs in South Africa.<sup>5</sup> This achievement was recently tarnished by increasing alarm over Free State province's public sector ARV programme. The Free State has the third-highest HIV prevalence (of 31%) in the country.<sup>6</sup> Since December 2008, the province's Department of Health stopped initiating new patients on ARVs<sup>7</sup> because of out-of-stock drugs and lack of funds. An estimated 30 PLWHs are dying every day in the province while this hiatus continues.<sup>8</sup> The moratorium will increase morbidity and mortality, but the loss of trust in the health system and the potential impact of the ARV crisis on existing patient adherence also need to be considered.

Campero *et al.* reported that patients already on ARVs share their medication with neighbours, relatives or friends who experience delays in receiving ARVs.<sup>9</sup> This practice could lead to the development of drug resistance in people sharing medication if they consequently have differential exposure to ARVs,<sup>10-13</sup> and raises serious public health concerns about drug failure, subsequent and more expensive drug regimens, and the spread of drug-resistant strains of HIV.

Patients' perceptions of staff attitudes and waiting times were reported to be key factors for patients' ARV adherence.<sup>14</sup> Conceivably, PLWHs will seek care in other provinces, and would consequently be required to return monthly to outlying clinics to pick up their ARVs. Transport costs and the time needed to reach clinics are risk factors to adherence and retention in care.<sup>15,16</sup> Patients currently on treatment – in the Free State and elsewhere – are understandably anxious about the health system's ability to guarantee lifelong access to ARVs.

An estimated 300 000 people might not have died of AIDS if the South African government had responded to the AIDS crisis quickly and in a coherent manner.<sup>17</sup> How the government proceeds to contain and repair the damage being done in the Free State will be a litmus test for the long-term success of South Africa's ARV programme.

### Ziad El-Khatib

Division of Global Health (IHCAR)  
Karolinska Institutet  
Stockholm  
Sweden  
ziad.el-khatib@ki.se

### Marlise Richter

Steve Biko Centre for Bioethics  
University of the Witwatersrand  
Johannesburg  
marlise.richter@gmail.com



1. Moatti JP, Spire B, Kazatchkine M. Drug resistance and adherence to HIV/AIDS antiretroviral treatment: against a double standard between the north and the south. *AIDS* 2004; 18 (suppl 3): S55-61.
2. Check E. Staying the course. *Nature* 2006; 442: 617-619.
3. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America. *JAMA* 2006; 296: 679-690.
4. Bangsberg DR, Ware N, Simoni JM. Adherence without access to antiretroviral therapy in sub-Saharan Africa? *AIDS* 2006; 20: 140-141.
5. Speech by the Minister of Health Ms Barbara Hogan at the HIV Vaccine Research Conference (<http://www.doh.gov.za/docs/sp/sp1013-f.html>). In: Vaccine Research Conference; Cape Town 13 - 16 October 2008. Pretoria, Department of Health.
6. *National HIV and Syphilis Antenatal Sero-Prevalence Survey in South Africa 2006*. Pretoria: Department of Health, 2007.
7. ART crisis - Free State province, Dec. 2008. <http://www.sahivsoc.org>. (accessed 18 March 2009).
8. Thom A. 30 dying every day in the Free State - HIV Clinicians (<http://www.health-e.org.za/news/article.php?uid=20032192>). Health-e (accessed 19 February 2009).
9. Campero L, Herrera C, Kendall T, Caballero M. Bridging the gap between antiretroviral access and adherence in Mexico. *Qualitative Health Research* 2007; 17: 599-611.
10. Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. *J Infect Dis* 2008; 197: S272-S278.
11. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. *AIDS* 2006; 20: 223-231.
12. Boulle A, Ford N. Scaling up antiretroviral therapy in developing countries: what are the benefits and challenges? *Sex Transm Inf* 2007; 83: 503-505.
13. Gardner EM, Sharma S, Peng G, et al. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. *AIDS* 2008; 22: 75-82.
14. Dahab M, Charalambous S, Hamilton R, et al. 'That is why I stopped the ART': Patients' & providers' perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme. *BMC Public Health* 2008; 8:doi:10.1186/1471-2458-8-63.
15. Murray LK, Semrau K, McCurley E, et al. Barriers to acceptance and adherence of antiretroviral therapy in urban Zambian women: a qualitative study. *AIDS Care* 2009; 21: 78-86.
16. Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, Weiser SD. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: A qualitative study. *AIDS Behav* 2009; 13 March [Epub ahead of print].
17. Chigwedere P, Seage GR 3rd, Gruskin S, Lee TH, Essex M. Estimating the lost benefits of antiretroviral drug use in South Africa. *J Acquir Immune Defic Syndr* 2008; 49(4): 410-415.

## Are investigators satisfied with contract clinical research in South Africa?

**To the Editor:** In October 2008, I surveyed 75 principal investigators in South Africa with whom I had worked since 2004. I emailed to each a covering letter, a survey sheet with tick boxes for answers to 13 questions, and a comment sheet. I received completed surveys from 35 investigators. I could find no similar surveys in the literature.

The respondents are experienced investigators, of whom 66% had more than 5 years' experience in clinical trials, and a further 24% 2 - 5 years' experience; 37% had taken part in more than 5 trials in the previous 12 months, and a further 49% had taken part in 2 - 5 trials in the same period.

Investigator meetings were rated as 'good' by 51% of the investigators, and as 'average' by 43%; the supply of study materials to the site was rated as 'good' by 37% and 'average'

by 57%. Most respondents felt that the general conduct of the study was 'good' (71%), with nobody rating the conduct as 'bad'. The conduct of monitors was rated as 'good' by 63% of investigators, with nobody rating them as 'bad'.

Only 14% of investigators rated recruitment at their site as 'bad', while 6% described the sponsor's expectations of their site as 'bad'. The process of closing a study at the site was rated as 'good' by 74%.

A preference for electronic case report forms was stated by 59%, the rest preferring paper forms. Investigator fees were described as 'good' by 26% of investigators, and 'average' by 57%.

Only 3% of investigators felt that the time to Medicines Control Council (MCC) approval was 'good', with 80% rating the time as 'bad'.

Contract clinical research in South Africa has grown steadily in the last 5 years. This is the only survey that has been conducted to determine investigator satisfaction with the clinical trial industry. Investigators are generally satisfied with the process of conducting clinical research in South Africa, and are willing to utilise enhanced technology to stay abreast of the rest of the developing world in clinical trials. The time to MCC approval remains a concern but, with steps that are under way, I am certain that the dissatisfaction will change in the near future.

**E Mitha**

Newtown Clinical Research  
Johannesburg  
[emitha@iburst.co.za](mailto:emitha@iburst.co.za)

## Kebble or quibble?

**Dear Aunt Ethel,**

To those skilled at matters surgical, a lost orchid is the euphemism for an ectopic testis or undescended testicle. Makes Tretchikoff's originals/collectors' pieces sound like priceless balderdash, perhaps?

Yours affectionately

**Robert-Ian Caldwell**

Hilton, KwaZulu-Natal  
[ric@caldwells.co.za](mailto:ric@caldwells.co.za)